United States · 
Who invested in Parabase Genomics?
Parabase Genomics's investors include SXE Ventures and Walnut Ventures.
20132014
$970KSeed$2.0MSeries BUnited States · Series B startup
Who invested in Parabase Genomics
Funding summaryUpdated 26 Oct 2026
$3.0Mraised across 2 rounds since 2012, from 2 sources
$970KSeed$2.0MSeries B
- Latest round
- Series B, $2.0MNov 2014
- Step-upi
- 2.1×
- Investors
- 2
The funding story
Each circle is a round, placed by date and sized by amount. The line above is the running total.
- First round
- Seed, $970K Jul 2012
- Biggest round
- $2.0M Series B · Nov 2014
- Between rounds
- 2.3 years from the last two
The rounds
- Nov 2014
- Jul 2012Seed$970K
No investor was named in the report.
From a historical funding record
Founders and team
From Parabase Genomics's own website: 2 founders, 2 on the team.
Dr. Sarah ChenCEO & Co-Founder
Dr. James OkaforCTO & Co-Founder
- Dr. Mei-Ling ParkChief Scientific Officer
- Ricardo VasquezVP of Operations
Who was in which round
The busiest backers across the latest rounds. A filled square is a round they joined; a dark one, a round they led.
Everyone who backed them
Missing a round, or an investor who was in one? Tell us.
Quick answers about Parabase Genomics
How much has Parabase Genomics raised?
Parabase Genomics has raised $3.0M across 2 rounds since 2012.
When did Parabase Genomics last raise?
Parabase Genomics's most recent round was a Series B of $2.0M in Nov 2014.
What was Parabase Genomics's biggest round?
Its most recent round, $2.0M in Nov 2014, is also its largest on record.
Who backed Parabase Genomics first?
Parabase Genomics's first round on record, in Nov 2014, was backed by SXE Ventures and Walnut Ventures.
What stage is Parabase Genomics at?
Parabase Genomics's latest named round is a Series B, in Nov 2014.
Where is Parabase Genomics based?
Parabase Genomics is based in the United States.
Companies like Parabase Genomics
In the same sector, and raised in the last eighteen months.
Find investors like these
Search every investor by what they have actually funded, then narrow to your stage and market. Free.